BJMO - volume 16, issue 6, october 2022
G. Meert MD, D. Schrijvers MD, PhD
Giant cell tumour of the bone (GCTB) is an uncommon primary bone tumour with rare metastatic potential. Giant cell tumour of the jaw (GCTJ) is histologically similar to GCTB with comparable treatment options. Denosumab, a human monoclonal antibody working as a RANKL inhibitor is recommended for treating patients with unresectable giant cell tumours. However, data on long-term efficacy and toxicity (e.g. osteonecrosis of the jaw) remains scarce, especially in GCTJ. This article presents two cases of patients with a GCTJ who were treated with denosumab for over eight years with excellent disease control and without significant toxicity.
(BELG J MED ONCOL 2022;16(6):300–2)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
